YOU HAVE A CHOICE FOR THE MMR VACCINATION YOUR PATIENTS NEED

Children sitting around a ball

PRIORIX: an MMR vaccine from GSK

Indication for PRIORIX

PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.

blue-check-mark

Recommended by the Centers for Disease
Control and Prevention (CDC)

The CDC has published the recommendation that PRIORIX is an additional option to prevent MMR. The recommendations were published in the MMWR on November 18, 2022.1

 

You can find this MMWR on the Centers for Disease Control and Prevention website at CDC.gov.

Priorix-packaging

  

Ready to Experience PRIORIX?

 

Order from GSKDirect

Or contact your wholesaler/distributor.

Schedule fit

A seamless scheduling transition from your current MMR virus-containing vaccine.2,3

Get the details

Proven immune response2

The effectiveness of PRIORIX is based on a comparison of immune responses relative to M-M-R II.2

See the data

An MMR vaccine with syringes prefilled with Sterile Water Diluent Component2

Packaged with vials of Lyophilized Antigen Component, Live.2

Learn more

MMR=measles, mumps, and rubella; MMWR=Morbidity and Mortality Weekly Report.

Ball

INDICATION & IMPORTANT SAFETY INFO

INDICATION FOR PRIORIX

IMPORTANT SAFETY INFORMATION FOR PRIORIX

INDICATION FOR PRIORIX

PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.

IMPORTANT SAFETY INFORMATION FOR PRIORIX

  • Contraindications for PRIORIX: Do not administer PRIORIX to individuals with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine or after a previous dose of any measles, mumps, and rubella virus-containing vaccine. Do not administer PRIORIX to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. These individuals are at risk of disseminated vaccine virus infection. Do not administer PRIORIX to individuals who are pregnant. Pregnancy should be avoided for 1 month after vaccination
  • Appropriate medical treatment used to manage immediate allergic reactions must be available in the event an acute anaphylactic reaction occurs following administration of PRIORIX
  • There is a risk of febrile seizures following immunization with PRIORIX
  • Thrombocytopenia and thrombocytopenic purpura have been reported following vaccination with PRIORIX
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including PRIORIX. Procedures should be in place to avoid injury from fainting
  • The tip caps of the prefilled syringes of diluent contain natural rubber latex, which may cause allergic reactions
  • Vaccination with PRIORIX may not result in protection in all vaccine recipients
  • In clinical trials, the most commonly reported (≥10%) solicited adverse reactions were:
    • Age 12 through 15 months–local: pain (26%) and redness (25%); systemic: irritability (63%), loss of appetite (45%), drowsiness (45%), and fever (35%)
    • Age 4 through 6 years–local: pain (41%), redness (22%) and swelling (11%); systemic: loss of appetite (21%), drowsiness (27%), and fever (24%)
    • Age 7 years and older–local: pain (12%) and redness (12%)
  • Administration of immune globulins and other blood products concurrently with PRIORIX may interfere with the expected immune response to the vaccine
  • If a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or at least 4 weeks after PRIORIX to avoid false-negative results

Please see full Prescribing Information for PRIORIX.

References

  1. Measles, mumps, rubella vaccine (PRIORIX): recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR. 2022;71(46):1465-1470.

  2. Prescribing Information for PRIORIX.

  3. Prescribing Information for M-M-R II.